Rexahn Pharmaceuticals, Inc. Awarded Patent in Europe for Cancer Drug Archexin®
Published: Sep 12, 2013
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that the European Patent Office has granted the Company a patent, EP 1546180, for its clinical development candidate Archexin® and its use for inhibiting the activated form of Akt-1 (phospho-Akt1)for the treatment of cancer.
Help employers find you! Check out all the jobs and post your resume.